ANALIZE MEDICALE DE LABORATOR
Aici gasiti analizele medicale grupate pe categorii precum si detalii generale si specifice pentru categoriile respective.
Selectati o categorie din lista de mai jos:
Solutie antistress!
Construieste poduri :)
Prinde pisica neagra :)
Female Sexual Arousal Disorder, Positive Femprox Study Results
NexMed, Inc (Nasdaq: NEXM) announced the preliminary results from a 400 patient "at home" study conducted in China. The
multi-center study was randomized, double-blind, placebo-controlled, and designed to investigate the efficacy and safety of
three strengths of the Femprox® cream in pre-menopausal and post-menopausal women diagnosed with female sexual arousal
disorder ("FSAD"). Femprox is applied topically and incorporates alprostadil, a vasodilator, with the NexACT® permeation
technology. The results were announced at the Annual Meeting of the American Urological Association (AUA), Tuesday, May
21-26, 2005, in San Antonio, TX.
The patients, who were between the ages of 21 and 65, were randomly assigned to placebo or one of three strengths of Femprox.
They were required to use one application of Femprox prior to engaging in sexual activity, up to ten times during two
treatment evaluation periods. The primary efficacy end point was the arousal success rate determined by the internationally
recognized Female Sexual Encounter Profile (FSEP) questionnaire. Secondary efficacy end points included changes in the Female
Sexual Function Index (FSFI), in other FSEP responses, and in the Female Sexual Distress Scale (FSDS), as well as the Global
Assessment Question (GAQ).
The primary efficacy endpoint was statistically significant at the end of both evaluation periods. Patients showed
demonstrable improvement in sexual arousal over the course of therapy. At the end of the first evaluation period, 17% and
38.7% (p
Femeie sexual Arousal tulburare, rezultatele pozitive Femprox - Female Sexual Arousal Disorder, Positive Femprox Study Results - articole medicale engleza - startsanatate